Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.

Douglas L ArnoldColm ElliottEmily C MartinYann HyvertDavorka TomicXavier Montalban

Published in: Neurology (2024)

This study provides Class II evidence that evobrutinib reduces the volume of SELs assessed on MRI comparing baseline with week 48, in patients with RMS.

Keyphrases

multiple sclerosis
magnetic resonance imaging
white matter
contrast enhanced
randomized controlled trial
diffusion weighted imaging
systemic lupus erythematosus